Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Elevance Health Inc’s (ELV) EPS Reset—Is the Mismatched Rates & Utilization Wave Finally Engulfing All MCOs?
Elevance’s Q2F25 earnings reflected a deliberate EPS reset, cutting full-year guidance to ~$30 from ~$32–33, with over half of the downgrade tied to deteriorating ACA morbidity—driven by higher-acuity Medicaid disenrollees entering the individual market and lower effectuation among younger enrollees—and the balance from Medicaid acuity/utilization pressures. Adjusted EPS of $8.84 aligned with expectations, while operating revenue grew 14% y/y to $49.4B on pricing yield, Medicaid rate actions, and tuck-in asset contributions. MA remained a bright spot with stable utilization and disciplined bid posture for 2026. Medicaid margins are now seen positive but below long-term targets, as states lag in adjusting rates to elevated acuity. Management’s guidance embeds no risk-adjustment tailwinds, signaling conservative assumptions. Carelon delivered >50% y/y revenue growth in services and >20% in Rx, though pharmacy margins were diluted by specialty mix. Operating expense ratio improved 140bps to 10% via productivity and AI-enabled workflow gains. Capital returns totaled ~$380M, with share repurchases back-half weighted. At ~9.45x NTM P/E and 12% long-term EPS growth target intact, ELV’s moat rests on entrenched BCBS state leadership and Carelon’s scaling adjacencies. Can Elevance’s rate resets, AI-driven cost controls, and service diversification restore earnings momentum before policy and utilization headwinds further erode investor confidence?
